Medication info
Janumet Tablets 50/850 mg

Janumet Tablets 50/850 mg

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›56.7mg / 1 tabletMetformin Hydrochloride›850mg / 1 tablet
Manufacturer / importer
HLB Pharmaceuticals Co., Ltd.
Appearance
Oval-shaped film-coated tablet in dark pink color
Packaging
56 tablets/box [14 tablets/PTP×4], 30 tablets/bottle, 200 tablets/bottle
Approval status
Active

MFDS item code 202204564 · Approved 2022.12.21 · Insurance code 647304400

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this product should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This product is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. The initial dose of this product should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior experience with diabetes medication who cannot achieve adequate glycemic control with monotherapy, or for patients who cannot achieve adequate glycemic control with sitagliptin monotherapy, the initial dose is 1 tablet of this product 50/500 mg twice daily; this may be increased to 1 tablet of this product 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin must not be switched to this product (see Precautions for Use, 2. Patients Who Must Not Use This Product). 2. Patients receiving metformin: - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this product is a total daily dose of sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's current dose of metformin. - Patients switching from combination therapy with sitagliptin and metformin to this product may start at their current doses of sitagliptin and metformin. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this product is sitagliptin 50 mg twice daily (total daily dose 100 mg); the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When used with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this product. Any change in the treatment regimen for type 2 diabetes may affect glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This product may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other symptoms that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment with this product should not be initiated, since the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this product must be discontinued immediately. Patients with hepatic impairment This product must not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients Who Must Not Use This Product).

Ingredients

Manufacturer
HLB Pharmaceuticals Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication is used for patients with type 2 diabetes to help control blood sugar levels more effectively when combined with dietary and exercise regimens. Sitagliptin and metformin work together to improve blood sugar levels, thus providing positive effects for ongoing treatment.

How to take

Adult dose

For antidiabetic therapy, the dose of this product should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This product is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. The initial dose of this product should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior experience with diabetes medication who cannot achieve adequate glycemic control with monotherapy, or for patients who cannot achieve adequate glycemic control with sitagliptin monotherapy, the initial dose is 1 tablet of this product 50/500 mg twice daily; this may be increased to 1 tablet of this product 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin must not be switched to this product (see Precautions for Use, 2. Patients Who Must Not Use This Product). 2. Patients receiving metformin: - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this product is a total daily dose of sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's current dose of metformin. - Patients switching from combination therapy with sitagliptin and metformin to this product may start at their current doses of sitagliptin and metformin. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this product is sitagliptin 50 mg twice daily (total daily dose 100 mg); the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When used with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this product. Any change in the treatment regimen for type 2 diabetes may affect glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This product may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other symptoms that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment with this product should not be initiated, since the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this product must be discontinued immediately. Patients with hepatic impairment This product must not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients Who Must Not Use This Product).

Precautions

This medication consists of sitagliptin and metformin and is used in the treatment of diabetes. First, while taking this medication, there may be rare but serious allergic reactions, so if symptoms such as skin rash, hives, or difficulty breathing occur, stop taking it immediately and consult a physician. Additionally, this medication may cause severe inflammation of the pancreas known as pancreatitis. If symptoms such as abdominal pain, vomiting, or nausea occur, immediately inform medical personnel. The metformin component may cause lactic acidosis, a rare metabolic complication, associated with symptoms such as muscle pain, difficulty breathing, fatigue, and abdominal pain. If such symptoms arise, immediately discontinue the medication and go to the hospital. Patients with severely impaired kidney function, acute infection, dehydration, heart failure, or liver dysfunction should not use this medication, and patients scheduled for surgery should also stop taking it for a period of time. Regular monitoring of kidney function and blood tests should be performed while taking this medication, and it is advisable to periodically check vitamin B12 levels. Moreover, this medication can induce hypoglycemia, so regular meals should be maintained, and caution should be exercised when performing intense exercise. The risk of hypoglycemia may increase when taken alongside insulin or sulfonylurea medications. It is recommended that this medication not be used in pregnant or breastfeeding women and children under 18 years of age. Lastly, alcohol consumption may increase the risk of side effects, so avoiding alcohol during treatment is advisable.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory infection
  • headache
  • nausea
Show 19 more
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • peripheral edema
  • severe and disabling arthralgia
  • vesicular bullous pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • dyspnea
  • unstable angina
  • dizziness
  • decreased appetite
  • dermatitis
  • weight loss

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent air or humidity from entering. It is best to maintain a storage temperature between 1 to 30 degrees Celsius. This will help ensure the safety and effectiveness of the medication.

Appearance and packaging

Appearance

Oval-shaped film-coated tablet in dark pink color

Package unit

56 tablets/box [14 tablets/PTP×4], 30 tablets/bottle, 200 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.